Cancer/Tumor Profiling Market Size to Reach USD 18.13 Billion in 2028, Says Reports and Data

Increasing investments by various major players for advancements in the oncology field and rapid growth of the healthcare sector, particularly in developing countries, are driving market revenue growth.

Increasing investments by various major players for advancements in the oncology field and rapid growth of the healthcare sector, particularly in developing countries, are driving market revenue growth

The global cancer/tumor profiling market size is expected to reach USD 18.13 Billion in 2028 and register a revenue CAGR of 10.3% over the forecast period, according to latest report by Reports and Data. Rising prevalence of various cancer types across the globe is one of the major factors driving cancer/tumor profiling market revenue growth. Governments of various countries worldwide are funding in technological developments for more advanced drugs and therapies to treat cancer. Additionally, rising awareness among people about importance of cancer detection at an early stage is driving demand for cancer profiling.

At present, cancer patients are usually prescribed with one or more treatment processes, such as surgery with chemotherapy or radiation therapy. These therapies are known to have several side effects. However, scientists have discovered ways of reducing side effects of such therapies by focusing on targeted treatment, a treatment involving attack on cancer cells only and preventing healthy cells from getting damaged. Cancer or tumor profiling is mandatory for proper use of targeted medicine to understand drug effectiveness for a particular type of cancer. This, in turn, is creating higher demand for cancer/tumor profiling among oncologists.

According to WHO, in 2020, there was an estimated rise in cancer cases by 19.3 Million, with 10 Million deaths worldwide. Among these new cases, breast and lung cancer accounted for 23.1% of all cancer cases. Rising number of cancer cases is invoking various major players to investment in development of innovative and more advanced technologies for cancer profiling, such as Chromogenic In Situ Hybridization (CISH). CISH has been designed specifically for detecting HER-2/neu oncogene amplification, and this gene confirms presence or absence of breast cancer. However, for chromosomal abnormalities, Fluorescence In Situ Hybridization (FISH) is considered as ideal option due to its accuracy and high resolution.

Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/4839

Some Key Highlights from the Report

  • Blood samples can detect cell-free DNA, circulating tumor cells, and exosomes, as well as macrovesicles. Inspite of having various pre-existing applications and purification processes, blood sampling is most commonly used for liquid biopsy studies and product innovations.
  • Immunohistochemistry (IHC) technology is widely accepted by laboratories to detect protein biomarkers in several types of cancers. Using mass spectrometry, this technology will be upgraded for detecting presence, abundance, location, and functional state of up to 100 targets.
  • In November 2021, Illumina and Sequoia Capital China jointly announced funding two startup companies poised to deliver breakthrough applications in genomics and multiomics. One startup company focuses on cutting-edge, single-cell sequencing technologies for molecular diagnostics applications, whereas the other is committed to building DNA, RNA epitome, and proteomics technology platforms for research and clinical applications.
  • As per WHO reports, there has been significant rise in cancer mortality cases in Africa and Asia due to inadequate number of specialized cancer hospitals, diagnostic centers, and institutes.
  • Companies profiled in the global market report include Thermo Fisher Scientific Inc., Illumina Inc., Siemens AG, F.Hoffmann La Roche Ltd, Nanostring Technologies Inc., BioGenex, NeoGenomics Laboratories Inc., HTG Molecular Diagnostics Inc., Perkin Elmer Inc., CellCarta Inc., Ribomed Biotechnologies Inc., Perthera, Qiagen N.V., and Personalis Inc.

Get In detailed Research Study @ https://www.reportsanddata.com/report-detail/cancer-and-tumor-profiling-market

For this report, Reports and Data has segmented the global cancer/tumor profiling market based on cancer type, technology, biomarker type, process type, application, and region:

Cancer Type Outlook (Revenue, USD Billion; 2018–2028)

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Stomach Cancer
  • Pancreatic Cancer
  • Thyroid Cancer
  • Sarcoid
  • Other

Technology Outlook (Revenue, USD Billion; 2018–2028)

  • Immunohistochemistry(IHC)
  • Fluorescence in situ Hybridization (FISH)
  • Next-Generation Sequencing (NGS)
  • Quantitative Polymerase Chain Reaction (qPCR)
  • Chromogenic in Situ Hybridization (CISH)
  • Microarray
  • Others

Biomarker Type Outlook (Revenue, USD Billion; 2018–2028)

  • Genetic
  • Protein
  • Others

Process Type Outlook (Revenue, USD Billion; 2018–2028)

  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics
  • Others

Application Outlook (Revenue, USD Billion; 2018–2028)

  • Research
  • Clinical
  • Machine learning

Buy Premium Research Report @ https://www.reportsanddata.com/report-pricing/4839

Regional Outlook (Revenue, USD Billion; 2018–2028)

  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. U.K.
    3. France
    4. Italy
    5. Spain
    6. Sweden
    7. BENELUX
    8. Rest of Europe
  • Asia-Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • Middle East & Africa
    1. Saudi Arabia
    2. UAE
    3. South Africa
    4. Israel
    5. Rest of MEA

Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/4839

Some points on how the report benefits stakeholders:

  • The reports include historical (2018–2020) and forecast (2021–2028) data points, revenues, and CAGR in table, figure, and chart formats, with detailed and qualitative, supporting written information for each.
  • Revenue break-up is provided for each segment in these formats for global, regional, and for each country in the respective region for each year between 2018 and 2028.
  • The report contains insights regarding growth drivers, restraints, opportunities, trends, company profiles, strategic developments, expansion details, product launches, and various other aspects related to the market.
  • The report contains data and information on customers, competitors, vendors/distributors, and other players and in the global marketplace.
  • Market research analysis is vital for all crucial business strategies and can aid in numerous ways and to provide a clearer understanding about strategies being deployed by competitors, product launches, competitive analysis, technological advancements and various other factors that enhance sales of a firm or perhaps provide insights to focus on merger and acquisition as a strategy or enter into strategic agreements or joint ventures etc.
  • The report contains company profiles of the top companies operating in the market along with their respective revenue and operating segments, geographical reach, market footprint, headquarters, growth rates, recent developments, product /services, expansion strategies, investments in expansion, and more.

Explore Latest Trending Research Reports By Reports and Data’s

Healthcare Supply Chain Management Market By Product (Software, Hardware, Services), By Mode of Delivery (Cloud-Based, On-Premise), By End Use (Healthcare Manufacturers, Healthcare Providers, Distributors, Logistics), And By Region Forecasts to 2028

Cell Signaling Market By Product Type (Endocrine Signaling, Paracrine Signaling, Autocrine Signaling, Juxtacrine Signaling, and Others), By Product (Consumables and Instruments), By Application (Research and Medical), By Pathway (Akt, AMPK, ErbB/HER, Hedgehog, JAK/SAT, NF-eB, Notch, and Others) By Technology (Microscopy, Western Blotting, Flow Cytometry, Immunohistochemistry, ELISA, Mass Spectrometry, and Other) and By Region Forecast to 2028

Interventional Neurology Device Market , By Product (Aneurysm Coiling & Embolization Devices, Cerebral Balloon Angioplasty & Stenting Systems, Support Devices, Neurothrombectomy Devices), By Disease Pathology (Ischemic Strokes, Cerebral Aneurysm, Carotid Artery Stenosis, Arteriovenous Malformations & Fistulas), By End, By Region, Forecast to 2028

Life Sciences Software Market , By Product Type (Cloud-based and On Premise), By End Use (Healthcare & Pharmaceuticals, Biotechnology, and Others), and By Region Forecast to 2028

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Read Latest Press Release @ https://www.reportsanddata.com/press-release/global-cancer-and-tumor-profiling-market